Open Orphan plc announced the signing of a new contract with a European Biotech Company for the provision of a RSV human challenge study. The study is projected to deliver £3.2 million in revenue all of which is expected to be recognised in 2020. If the study is successful, it is anticipated that an additional follow-on larger pivotal challenge study will commence end fourth quarter of 2020, delivering significant further revenue and expected to be a minimum of £7 million.